Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More
Prakash Diwan of prakashdiwan.in is of the view that Lupin may test Rs 2600-2700.
Deepak Shenoy of capitalmind.in has a positive stance on Sun Pharmaceutical Industries and Strides Arcolab.
Deepak Shenoy, Founder of Capitalmind.in likes Sun Pharma and Strides Arcolab and feels that pharma as a space is worth looking into.
Pharma Analyst Surajit Pal is not very keen on holding pharma biggies, given the newsflows that are associated with them. Lupin first quarter earnings have been disappointing and Pal believes the pain is going to continue for two-three months. Another big-ticket stock Sun Pharma too have seen a steep fall after it issued profit warning.
Devang Mehta of Anand Rathi Financial Services recommends accumulating Sun Pharmaceutical Industries with a view of 18-24 months.
Anand Tandon, Market Expert is of the view that one may prefer Glenmark Pharma.
Mahantesh Sabarad, Deputy VP of Research at SBI Capital Securities recommends buying Sun Pharmaceutical Industries.
Sachin Shah of Emkay Investment Managers is of the view that one may see 5-7 percent downside in Sun Pharmaceutical Industries.
Deepak Shenoy of Capital Mind is of the view that one may prefer Strides Arcolab and Sun Pharma.
Gaurang Shah of Geojit BNP Paribas Financial Services is of the view that one may hold Reliance Industries with a target Rs 980.
Mayuresh Joshi - fund manager - PMS at Angel Broking recommends holding Sun Pharma.
Watch the interview of Mayuresh Joshi of Angel Broking to answer all your stock queries and Kalpesh Ashar of Full Circle Financial Planners & Advisors is answer our few personal finance queries.
According to Mayuresh Joshi of Angel Broking, one may stay invested in Sun Pharmaceutical Industries.
Abhishek Sharma, pharma analyst at IIFL is of the view that one may see upside in Sun Pharmaceutical Industries.
Pharma Analyst, Abhishek Sharma of IIFL spoke with Ekta Batra & Anuj Singhal of CNBC-TV18. He shared his reading and outlook on the pharmaceutical space.
Mayuresh Joshi of Angel Broking is of the view that one may invest in Sun Pharmaceutical Industries.
or the investors who are holding the stock should continue to hold it but fresh entry should be made only if it corrects from the current levels, says Surajit Pal, pharma analyst at Prabhudas Lilladher.
Here are top 10 stocks to focus on March 24 â€“ HDFC, Wockhardt, Geometric, GMR Infra, Sun Pharma, Ranbaxy, Hero Moto, JSPL, Adani Power and Aarti Drugs.
Vishal Malkan of malkansview.com is of the view that one may exit Biocon.
Sandip Sabharwal of asksandipsabharwal.com is of the view that pharma could be a safe pocket.
VK Sharma of HDFC Securities recommends buying Ranbaxy Labs 780 Call.
Here are top 10 stocks to focus on March 4 - MindTree, Tata Global Beverages, Eicher Motors, Bharti Airtel, Idea Cellular, Adani Ports, Adani Power, Sesa Sterlite, JSPL and Nitesh Estates. The research team at CNBC-TV18 is also tracking Tata Motors, Ranbaxy, L&T Finance Holdings and APL Apollo Tubes.
Neeraj Deewan of Quantum Securities prefers Sun Pharmaceutical Industries.
VK Sharma of HDFC Securities is of the view that one may buy Lupin 1600 Call and Ranbaxy Labs 740 Call.
Meghana V Malkan of malkansview.com is of the view that one may buy Ranbaxy Laboratories and Apollo Tyres.